Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03580044 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT03580044 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT03580044, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-β-lactamase (MBL)- producing Gram-negative bacteria.
Interventions
- DRUG BAT
- COMBINATION_PRODUCT ATM-AVI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-12-25 |
| Est. Completion | 2023-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03580044
The ClinicalTrials.gov registry entry for NCT03580044 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BAT is the first listed.
NCT03580044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03580044 about?
NCT03580044 is a clinical study titled "Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria". Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) a...
What is the current status of trial NCT03580044?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2020-12-25. Estimated completion is 2023-01-23.
What interventions are being tested in trial NCT03580044?
The interventions under investigation include: BAT (DRUG), ATM-AVI (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03580044?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.